



Item 2.02. Results of Operations and Financial Condition.

On October 26, 2016 The Medicines Company (the “Company”) announced financial results for the three and nine months ended September 30, 2016. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:

99.1 Press release dated October 26, 2016 entitled “The Medicines Company Reports Third-Quarter 2016 Financial Results”

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

THE MEDICINES COMPANY

Date: October 26, 2016

By: /s/ Stephen M. Rodin

Stephen M. Rodin

Executive Vice President and General Counsel

---

Exhibit Index

Exhibit No.	Description
99.1	Press release dated October 26, 2016 entitled “The Medicines Company Reports Third-Quarter 2016 Financial Results”